Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Inventory (2016 - 2026)

Ekso Bionics Holdings has reported Inventory over the past 13 years, most recently at $4.8 million for Q4 2025.

  • On a quarterly basis, Inventory rose 5.49% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 5.49% increase, with the full-year FY2025 number at $4.8 million, up 5.49% from a year prior.
  • Inventory reached $4.8 million in Q4 2025 per EKSO's latest filing, down from $5.0 million in the prior quarter.
  • The five-year high for Inventory was $5.7 million in Q1 2023, with the low at $1.8 million in Q3 2021.
  • The 5-year median for Inventory is $5.0 million (2024), against an average of $4.2 million.
  • Peak YoY movement for Inventory: dropped 19.68% in 2021, then surged 131.36% in 2022.
  • Tracing EKSO's Inventory over 5 years: stood at $2.2 million in 2021, then surged by 131.36% to $5.2 million in 2022, then decreased by 2.64% to $5.0 million in 2023, then fell by 9.49% to $4.6 million in 2024, then rose by 5.49% to $4.8 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $4.8 million, $5.0 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.